S284
Clinical - Breast
ESTRO 2026
perception, psychological outlook, and breast-related symptoms. These findings support the patient-centred value of shorter radiotherapy schedules, which reduce treatment burden, hospital visits, and potential disruption to daily life, while maintaining favorable tolerance profiles. The study reinforces the growing evidence that ultra-hypofractionated WBI is a safe, effective, and QoL-enhancing option for early-stage breast cancer. Keywords: Quality of life, ultra-hypofractionation Proffered Paper 2685 10-year Follow-Up of the DBCG HYPO Trial: Breast Induration, Recurrence and Survival After Hypofractionated Whole Breast Irradiation Hanna Forsberg 1 , Jan Alsner 1 , Hanne M. Nielsen 2 , Else Maae 3 , Mette H. Nielsen 4 , Mechthild Krause 5 , Marie LH Milo 6 , Ingvil Mjaaland 7 , Andreas Schreiber 8 , Unn- Miriam Kasti 9 , Jens Overgaard 1 , Birgitte V. Offersen 1,2 1 Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark. 2 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 3 Department of Oncology, Vejle Hospital, Vejle, Denmark. 4 Department of Oncology, Odense University Hospital, Odense, Denmark. 5 Department of Radiation Oncology and OncoRay Center, University Hospital and Faculty of Medicine Carl Gustav Carus; Technische Universität Dresden; German Cancer Consortium Dresden; Helmholtz- Zentrum Dresden-Rossendorf; National Center for Tumor Diseases, Dresden; and German Cancer Research Center, Heidelberg, Germany. 6 Department of Oncology, Aalborg University Hospital, Aalborg, Denmark. 7 Department of Oncology, Stavanger University Hospital, Stavanger, Norway. 8 Department of Oncology, Academic Teaching Hospital Dresden- Friedrichstadt, Dresden, Germany. 9 Department of Oncology, Kristiansand Hospital, Kristiansand, Norway Purpose/Objective: In 2014, the Danish Breast Cancer Group (DBCG) radiotherapy (RT) guidelines changed from 50 Gy in 25 fractions (fr) to 40 Gy in 15 fractions for whole breast RT of patients operated with breast conservation for node-negative breast cancer or ductal carcinoma in situ (DCIS). This was based on the early results from the DBCG HYPO trial demonstrating similar risk of 3- year breast induration and similar recurrence pattern (1). This analysis reports 10-year outcomes for breast induration, recurrence pattern, and mortality. Material/Methods: The DBCG HYPO trial randomized 1,882 women with node-negative breast cancer or DCIS with indication for breast-only RT to 50Gy/25fr versus 40Gy/15fr. Three-year breast induration grade ≥ 2 was the
retrospective-prospective, multicentre observational study was designed. This analysis focuses on QoL changes one year after treatment completion. Material/Methods: The study was conducted across multiple Italian Radiation Oncology Centres in accordance with the Declaration of Helsinki and Good Clinical Practice; ethical approval and clinical trial registration were obtained. Eligible patients had ductal carcinoma in situ or invasive early-stage breast cancer and were treated with BCS and ultra-hypofractionated WBI (26 Gy in 5 fractions). A sequential or simultaneous integrated boost was allowed. QoL was assessed using the EORTC QLQ-C30 and QLQ-BR23 questionnaires administered before radiotherapy and one year after completion. Results: A total of 2036 patients were enrolled from 28 centres; 570 (28%) from 15 centres completed both baseline and one-year QoL assessments. Patients showed a significant improvement in global health status (p=0.020), future perspective (p<0.001), and breast symptoms (p<0.001) one year after treatment (Tab1). Analysis of individual breast symptom items revealed significant reductions in pain (p=0.002), swelling (p=0.004) and oversensitivity (p<0.001). Skin-related symptoms improved but did not reach statistical significance (Tab2). Overall, the results indicate a positive trend in both local and global QoL domains following ultra-hypofractionated WBI.
Conclusion: Ultra-hypofractionated WBI was associated with meaningful improvements in patient-reported QoL at one year, particularly regarding global health
Made with FlippingBook - Share PDF online